1466 related articles for article (PubMed ID: 11448283)
1. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
[TBL] [Abstract][Full Text] [Related]
2. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
[TBL] [Abstract][Full Text] [Related]
3. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.
Persaud D; Siberry GK; Ahonkhai A; Kajdas J; Monie D; Hutton N; Watson DC; Quinn TC; Ray SC; Siliciano RF
J Virol; 2004 Jan; 78(2):968-79. PubMed ID: 14694128
[TBL] [Abstract][Full Text] [Related]
4. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients.
Paolucci S; Baldanti F; Campanini G; Zavattoni M; Cattaneo E; Dossena L; Gerna G
J Med Virol; 2001 Oct; 65(2):207-17. PubMed ID: 11536225
[TBL] [Abstract][Full Text] [Related]
5. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
6. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
[TBL] [Abstract][Full Text] [Related]
7. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads.
Kieffer TL; Finucane MM; Nettles RE; Quinn TC; Broman KW; Ray SC; Persaud D; Siliciano RF
J Infect Dis; 2004 Apr; 189(8):1452-65. PubMed ID: 15073683
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
[TBL] [Abstract][Full Text] [Related]
9. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
[TBL] [Abstract][Full Text] [Related]
10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
[TBL] [Abstract][Full Text] [Related]
12. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
[TBL] [Abstract][Full Text] [Related]
13. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.
Tobin NH; Learn GH; Holte SE; Wang Y; Melvin AJ; McKernan JL; Pawluk DM; Mohan KM; Lewis PF; Mullins JI; Frenkel LM
J Virol; 2005 Aug; 79(15):9625-34. PubMed ID: 16014925
[TBL] [Abstract][Full Text] [Related]
14. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
15. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
[TBL] [Abstract][Full Text] [Related]
16. Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia.
Ross L; Johnson M; DeMasi R; Liao Q; Graham N; Shaefer M; St Clair M
AIDS; 2000 May; 14(7):813-9. PubMed ID: 10839589
[TBL] [Abstract][Full Text] [Related]
17. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
[TBL] [Abstract][Full Text] [Related]
18. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.
Verhofstede C; Van Wanzeele F; Van Der Gucht B; Pelgrom J; Vandekerckhove L; Plum J; Vogelaers D
J Med Virol; 2007 Sep; 79(9):1254-60. PubMed ID: 17607772
[TBL] [Abstract][Full Text] [Related]
19. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D;
AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228
[TBL] [Abstract][Full Text] [Related]
20. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]